Dr Reddy’s received US FDA approval for its rituximab biosimilar, expanding its US market presence. Fresenius Kabi will commercialize it.
Dr Reddy’s received US FDA approval for its rituximab biosimilar, expanding its US market presence. Fresenius Kabi will commercialize it.